Recursion Pharmaceuticals Inc
NASDAQ:RXRX

  • LAST PRICE
    9.0200
  • TODAY'S CHANGE (%)
    -0.0700 (-0.7701%)
  • Bid / Lots
    8.8600/ 8
  • Ask / Lots
    9.2000/ 38
  • Open / Previous Close
    9.0000 / 9.0900
  • Day Range
    8.7202
    9.2200
  • 52 Week Range
    4.9700
    16.7450
  • Volume
    3,384,230

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
RXRX
Recursion Pharmaceuticals Inc
2.0B
-5.6x
---
NTLA
Intellia Therapeutics Inc
2.1B
-4.3x
---
AGIO
Agios Pharmaceuticals Inc
2.1B
-7.6x
---
KYMR
Kymera Therapeutics Inc
2.0B
-13.1x
---
RCKT
Rocket Pharmaceuticals Inc
1.9B
-8.0x
---
VERA
Vera Therapeutics Inc
2.1B
-18.6x
---
As of 2024-06-06

Company Information

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Contact Information

Headquarters
41S Rio Grande StreetSALT LAKE CITY, UT, United States 84101
Phone
385-269-0203
Fax
801-581-7895

Executives

Independent Chairman of the Board
Robert Hershberg
President, Chief Operating Officer
Tina Larson
Chief Executive Officer, Director
Christopher Gibson
Chief Financial Officer
Michael Secora
Director, Chief Research and Development Officer, Chief Commercial Officer
Najat Khan

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.0B
Revenue (TTM)
$46.2M
Shares Outstanding
237.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.62
Book Value
$1.98
P/E Ratio
-5.6x
Price/Sales (TTM)
42.6
Price/Cash Flow (TTM)
---
Operating Margin
-814.39%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.